Oral administration of MT-1303 at 0.1 and 0.3 mg/kg was efficacious against chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells, a murine IBD model, and its efficacy was comparable to that of an anti-mTNF-α mAb. This evidence concerns the gene CD4 and inflammatory bowel disease.